Page 8 - Trisha Roy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(Reuters) - The U.S. Food and Drug Administration is preparing to authorize Pfizer Inc and German partner BioN...

By Syndicated Content May 4, 2021 | 6:33 PM (Reuters) – The United States has administered 247,769,049 doses of COVID-19 vaccines in the country as of Tuesday morning and distributed 318,474,035 doses, the U.S. Centers for Disease Control and Prevention (CDC) said on Tuesday. Those figures are up from the 246,780,203 vaccine doses the CDC said had gone into arms by Monday out of 312,509,575 doses delivered. The agency said 147,894,671 people had received at least one dose while 106,168,588 people are fully vaccinated as of Tuesday. The CDC tally includes two-dose vaccines fro...

U.S. FDA set to authorize Pfizer COVID-19 shot for ages 12-15 early next week An approval is highly anticipated after the drugmakers said in March that the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year-olds in a clinical trial. Written By: Reuters | × A vial and sryinge are seen in front of a displayed Pfizer logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo May 3 (Reuters) - The U.S. Food and Drug Administration is preparing to authorize Pfizer Inc and German partner BioNTech SE's COV...

By Syndicated Content May 3, 2021 2:19 PM (Reuters) – The United States has administered 246,780,203 doses of COVID-19 vaccines in the country as of Monday morning, the U.S. Centers for Disease Control and Prevention said on Monday. The figure is up from the 245,591,469 vaccine doses the CDC said had gone into arms by Sunday out of 312,509,575 doses delivered. The agency said 147,517,734 people had received at least one dose while 105,523,520 people are fully vaccinated as of Monday. The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech, as well as Johnso...

(Adds FDA and Pfizer comments, background) May 3 (Reuters) - The U.S. Food and Drug Administration is preparing to authorize Pfizer Inc and German partner BioNTech SE's COVID-19 vaccine for adolescents aged between 12 and 15 years by early next week, the New York Times reported on Monday, citing federal officials familiar with the agency's plans. An approval is highly anticipated after the drugmakers said in March that the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year-olds in a clinical trial. Responding to a Reuters request for comment, the ...